

Neola Medical to present at Redeye MedTech & Diagnostics Event

Neola Medical AB will present the latest developments at the Redeye Theme: MedTech & Diagnostics Event hosted by Redeye on November 13, 2024 at 13:05 CET (13.05). Tune in to watch CEO Hanna Sjöström present live from New York City at: <https://www.redeye.se/events/1016182/redeye-theme-medtech-diagnostics-3>

"I look forward to share an update on Neola Medical's business progress. This year, we have hit major milestones toward U.S. market approval and are entering the crucial clinical validation phase, preparing for our first pivotal study on preterm born babies in the U.S.—a critical step toward our FDA application.", says CEO Hanna Sjöström.

The presentation will also be accessible for viewing afterward on www.redeye.se and our company website at www.neolamedical.com

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Neola Medical to present at Redeye MedTech & Diagnostics Event](#)